Latest news with #Dexamethasone
&w=3840&q=100)
Business Standard
30-05-2025
- Business
- Business Standard
Gland Pharma stock volatile after announcing Q4 results, dividend; Details
Gland Pharma share price slipped 2 per cent in the morning deals, however, its losses reversed and the stock was trading 4.9 per cent higher on BSE. The volatility in the stock came after the company reported its Q4 results. At 9:55 AM, Gland Pharma shares were up 4.14 per cent at ₹1,558 per share on the BSE. In comparison, the BSE Sensex was up 0.66 per cent at 81,721.26. The market capitalisation of the company stood at ₹25,669.05 crore. The 52-week high of the stock was at ₹2,220.95 per share and the 52-week low of the stock was at ₹1,200 per share. Gland Pharma Q4 results 2025 The company announced its fourth quarter (Q4FY25) results on May 20, 2025, after market hours. The company's consolidated net profit after tax (PAT) stood at ₹186.5 crore as compared to ₹192.4crore a year ago, down 3 per cent year-on-year (Y-o-Y). Its revenue from operations also slipped 7 per cent at ₹1,424.9 crore for Q4 against ₹1,537.5 crore a year ago. Its Earnings before interest, tax, depreciation, and amortisation (Ebitda) stood at ₹347.5 crore as compared to ₹358.7 crore a year ago. The Ebitda margin for the quarter came in at 24 per cent against 23 per cent Y-o-Y. According to the filing, research and development (R&D) expenses were ₹50.3 crore in Q4 FY25, representing 4.9 per cent of revenue, while for FY25 were ₹192.2 crore (4.7 per cent of revenue). The company launched four new molecules, including Latanoprost, Midazolam Bags RTU, Dexamethasone, and Vancomycin (New Strengths), which were launched in Q4 FY25, contributing to 31 cumulative launches in FY25. In the quarter under review, five Abbreviated New Drug Application (ANDAs) were filed and seven were approved, with a total of 24 ANDAs filed and 32 ANDAs approved in FY25, contributing to a cumulative total of 371 ANDA filings in the US (318 approved, 53 pending). Gland Pharma dividend The board of Gland Pharma recommended a final dividend of ₹18 per equity share for FY25, pending shareholder approval. About Gland Pharma Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer [HK1] of small volume liquid parenteral products, to become one of the largest and fastest growing generic injectables manufacturing companies, with a global footprint across 60 countries, including the US, Europe, Canada, Australia, India and other markets.
Yahoo
26-05-2025
- Health
- Yahoo
Dietary supplements containing drugs recalled due to serious health risks
Umary USA announced a voluntary recall of dietary supplements marketed nationwide for joint pain and arthritis relief as they contain drugs that pose serious health risks, according to the U.S. Food and Drug Administration. All lots and dates of the supplements, Unavy Ácido Hialurónico and Umovy Ácido Hialurónico caplets, are covered by the recall. Consumers who purchased the supplements should immediately stop taking them and consult their health care provider for safe discontinuation of use. The caplets contain the undeclared drugs diclofenac, dexamethasone and omeprazole, according to the FDA. Because they contain those drugs, they cannot be marketed as dietary supplements. Their safety and effectiveness have not been established, according to the FDA. 'Dexamethasone, a corticosteroid, can weaken the immune system, cause high blood sugar, muscle damage, psychiatric effects and cardiovascular problems,' the FDA press release states. 'Prolonged or high-dose use may suppress adrenal gland function and abrupt stopping can lead to withdrawal symptoms.' 'Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), may cause severe cardiovascular, gastrointestinal, kidney, and allergic reactions, especially in patients taking other NSAIDs or blood thinners or those with allergies or underlying health issues,' the statement reads. 'Omeprazole, a proton pump inhibitor used to treat stomach acid disorders, might mask serious gastric conditions such as ulcers or cancer if taken unknowingly,' the statement reads. Unavy Ácido Hialurónico comes in a white plastic bottle with a black label marked with white and yellow text. Umovy Ácido Hialurónico is packaged in a black plastic bottle with a black label featuring white and blue lettering. Both products come in 30-count, 850-mg caplets. The supplements were distributed nationwide by Umary USA, which is notifying distributors and customers by press release and email. The company is arranging for returns and refunds, according to the FDA. There have been no reported adverse reactions linked to using the two products. Consumers who are experiencing problems related to the caplets should contact their healthcare provider and report issues to the FDA's MedWatch program online. For questions about the recall, consumers can contact Umary USA at umaryusa2025@ available 24/7. For more information, visit the official FDA recall notice here. Multi-state salmonella outbreak linked to recalled cucumbers Public health alert: Listeria found in Big Y, Price Chopper ready-to-eat wrap Tattoo ink recalled due to contamination with infection-causing microorganisms Read the original article on MassLive.
&w=3840&q=100)
Business Standard
21-05-2025
- Business
- Business Standard
Gland Pharma stock volatile after announcing Q4 results, dividend; Details
Gland Pharma share price slipped 2 per cent in the morning deals, however, its losses reversed and the stock was trading 4.9 per cent higher on BSE. The volatility in the stock came after the company reported its Q4 results. At 9:55 AM, Gland Pharma shares were up 4.14 per cent at ₹1,558 per share on the BSE. In comparison, the BSE Sensex was up 0.66 per cent at 81,721.26. The market capitalisation of the company stood at ₹25,669.05 crore. The 52-week high of the stock was at ₹2,220.95 per share and the 52-week low of the stock was at ₹1,200 per share. Gland Pharma Q4 results 2025 The company announced its fourth quarter (Q4FY25) results on May 20, 2025, after market hours. The company's consolidated net profit after tax (PAT) stood at ₹186.5 crore as compared to ₹192.4crore a year ago, down 3 per cent year-on-year (Y-o-Y). Its revenue from operations also slipped 7 per cent at ₹1,424.9 crore for Q4 against ₹1,537.5 crore a year ago. Its Earnings before interest, tax, depreciation, and amortisation (Ebitda) stood at ₹347.5 crore as compared to ₹358.7 crore a year ago. The Ebitda margin for the quarter came in at 24 per cent against 23 per cent Y-o-Y. According to the filing, research and development (R&D) expenses were ₹50.3 crore in Q4 FY25, representing 4.9 per cent of revenue, while for FY25 were ₹192.2 crore (4.7 per cent of revenue). The company launched four new molecules, including Latanoprost, Midazolam Bags RTU, Dexamethasone, and Vancomycin (New Strengths), which were launched in Q4 FY25, contributing to 31 cumulative launches in FY25. In the quarter under review, five Abbreviated New Drug Application (ANDAs) were filed and seven were approved, with a total of 24 ANDAs filed and 32 ANDAs approved in FY25, contributing to a cumulative total of 371 ANDA filings in the US (318 approved, 53 pending). NHPC Q4 results | Fortis Healthcare Q4 profit drops 7% Gland Pharma dividend The board of Gland Pharma recommended a final dividend of ₹18 per equity share for FY25, pending shareholder approval. About Gland Pharma Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer [HK1] of small volume liquid parenteral products, to become one of the largest and fastest growing generic injectables manufacturing companies, with a global footprint across 60 countries, including the US, Europe, Canada, Australia, India and other markets.
Yahoo
25-03-2025
- Health
- Yahoo
U.S. Customs seizes 102,000 banned pills in Cincinnati
March 25 (UPI) -- U.S. Customs and Border Protection intercepted 102,000 banned Artri King nutritional supplement pills worth an estimated $47,000 at the Cincinnati Port of Entry over the weekend. The pills were shipped by the same entity in Mexico and were destined for the same residence in California, CBP officials said Tuesday in a news release. The customs declaration for six packages containing the pills describes them as "Nutritional Supplement Natural INGR," according to the CBP. "Most people hear about CBP seizing narcotics shipments," CBP Chicago Field Office director of operations LaFonda Sutton-Burke said. "Shipments of unapproved pills are very dangerous, too." Sutton-Burke said the U.S. Food and Drug Administration has not approved the potentially dangerous pills. The pills "contain harmful chemicals which can lead to medical emergencies or even death," Simon-Burke said. The Artri King pills are promoted as treatment for muscle pain, arthritis, osteoporosis, bone cancer and other conditions and are sold through some retail stores and websites, such as and FDA lab analyses show the pills contain undeclared ingredients and are associated with liver toxicity and deaths. The FDA in April 2022 issued a warning saying the pills contain diclofenac and dexamethasone, neither of which are listed among its ingredients. "Consumers taking Artri King should immediately consult with their health care professional to safely discontinue use of this product," the FDA warning says. Dexamethasone is a corticosteroid that FDA officials say commonly is used to treat inflammatory conditions. Corticosteroids can impair a person's ability to fight infections and could cause high blood sugar levels, muscle injuries and psychiatric problems, according to the FDA. When taken over an extended periods or in high doses, they can suppress the adrenal gland, cause withdrawal symptoms and cause serious side effects when combined with other medications. Diclofenac is a non-steroidal and anti-inflammatory drug commonly referred to as "NSAIDs" that could increase users' risks of heart attack, stroke and other cardiovascular medical events. The drug also could cause serious gastrointestinal damage, including bleeding, ulcers and fatal perforations of the stomach and intestines. It also might interact with other medications and significantly increase the risk of harmful medical reactions.
